Latest Breaking News On - Guanylate cyclase sgc - Page 1 : comparemela.com

Technology Advancements such as Biomaker and New Gene Therapy for the Treatment Segments Covered Based on Drug Class, the pulmonary arterial hypertension (PAH) market has been segmented into Soluble Guanylate Cyclase (SGC) stimulators, prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), and Endothelin Receptor Antagonists (ERA). ERA And Prostacyclin And Prostacyclin Analogs for treating PAH have the largest market share owing to the significant increase in the sales of this drug for the treatment of pulmonary arterial hypertension. Based on Distribution Mode, Online Pharmacies is expected to grow at the highest CAGR during the forecast period. An increase in preferences for e-commerce platforms and also due to the benefits provided by the online pharmacies like discounts & home delivery are fueling the growth of the market.

United statesUnited kingdomDong coSouth africaUnited arab emiratesSaudi arabiaSouth koreaGuanylate cyclase sgcLaura woodGuanylate cyclaseDaiichi sankyo companyGlaxosmithkline plcDonga st co ltdBristol myers squibb companyGilead sciences incArena pharmaceuticals